Gralla R J
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Semin Oncol. 1988 Dec;15(6 Suppl 7):8-12.
In non-small cell lung cancer (NSCLC), if the tumor is completely resected in stage I, II, and IIIa disease, the outlook is favorable. In stage IIIa disease, preoperative chemotherapy is efficacious and also confers the potential for improved resectability rates and survival. In a study of 58 patients with locally advanced (stage IIIa) NSCLC, preoperative combination chemotherapy with mitomycin C, cisplatin, and vinca alkaloids yielded 7 complete responses and 37 partial responses. Of the 44 patients with major responses, 42 were surgically explored and 33 were completely resected. Nine patients had pathologically negative biopsy specimens. The median survival for all patients thus far is 19.5 months. These results indicate that surgery can be performed safely in patients treated preoperatively with currently available chemotherapeutic agents. Moreover, complete resections are feasible and can be accomplished in a majority of patients.
在非小细胞肺癌（NSCLC）中，如果肿瘤在I期、II期和IIIA期疾病中被完全切除，预后良好。在IIIA期疾病中，术前化疗是有效的，并且还具有提高切除率和生存率的潜力。在一项针对58例局部晚期（IIIA期）NSCLC患者的研究中，术前使用丝裂霉素C、顺铂和长春花生物碱进行联合化疗产生了7例完全缓解和37例部分缓解。在44例有主要缓解的患者中，42例接受了手术探查，33例被完全切除。9例患者的活检标本病理检查为阴性。到目前为止，所有患者的中位生存期为19.5个月。这些结果表明，使用目前可用的化疗药物进行术前治疗的患者可以安全地进行手术。此外，完全切除是可行的，并且在大多数患者中可以实现。
